Citius Oncology secures up to $36.5M in debt and warrant exercise proceeds

CITIUS ONCOLOGY, INC.

Warrant inducement yields ~$11.5M gross from exercise of 12.8M shares at $0.90; new warrants for 25.6M shares at $0.90.
Avenue Capital Group provides up to $25M senior secured credit facility; $10M initial tranche funded at close.
Avenue also receives warrants to buy up to 11.1M shares at $0.90 exercisable after stockholder approval.
Parent debt subordinated to new loan; promissory note amended to align with 91-day post-Senior Debt maturity.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

CITIUS ONCOLOGY, INC. entered into Warrant Inducement Agreement with the holder of certain existing warrants valued at approximately $11.5 million (effective 2026-05-05).

Action: entry
Counterparty: the holder of certain existing warrants
Value: approximately $11.5 million
Effective: 2026-05-05

Exact text from the filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

View on SEC.gov

23 material agreements filed in the last 30 days. Browse all material agreements →

CITIUS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-052552

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.